Market Overview:
The global congenital heart disease market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of congenital heart diseases, increasing awareness about CHD, and technological advancements in the field of cardiac surgery. However, the high cost of treatment and lack of skilled professionals are some factors that are restraining the growth of this market. The global congenital heart disease market is segmented on the basis of type, application, and region. On the basis of type, it is divided into medication therapy and surgical therapy. The medication therapy segment dominates this market owing to its low cost and easy availability as compared to surgical therapy. By application, it is classified into hospitals & clinics and diagnostic centres segments.
Product Definition:
A congenital heart defect is a problem with the structure of the heart that is present at birth. Congenital heart defects can affect the way blood flows through the heart. They can also affect how well the heart works.
Medication:
Medication is the use of drugs or medication to treat a medical condition. In CHD, there are various conditions that require the usage of medications such as folic acid for prevention and treatment of heart defects in infants; digitalis for cardiac stimulation; diuretics for congestive heart failure; digitalis glycoside and procainamide for arrhythmias among others.
Surgical Therapy:
Surgical therapy and it's usage in congenital heart disease market is used to treat the conditions resulting from a hole in the heart. The surgical procedures are done to close or repair congenital defects in various parts of the body such as mitral and ventricular septum, pulmonary outflow obstructions, etc. Surgical therapy includes open surgery (cardiac surgery), minimally invasive surgeries, and cardiac catheterization.
Application Insights:
Based on application, the global congenital heart disease market is segmented into hospitals and clinics, diagnostic centers and other facilities. Hospitals and clinics held the largest share in 2017 owing to availability of advanced healthcare facilities along with a high number of patients suffering from CHD requiring medical attention.
The rise in prevalence of target diseases coupled with increasing patient awareness about treatment options is anticipated to boost hospital based therapy for these disorders over the forecast period. In addition, hospitals offer multidisciplinary care which includes cardiology consultation for diagnosis & treatment which further boosts segment growth. Hospital based therapy due to availability of highly skilled personnel as well as advanced healthcare facilities coupled with rising prevalence rates are anticipated to drive demand over the forecast period thus driving growth across all regions globally.
Regional Analysis:
North America dominated the global congenital heart disease market in 2017. This can be attributed to various factors such as favorable healthcare reimbursement policies, high per capita healthcare expenditure, and increasing awareness about CHD management. Moreover, the presence of key players in this region is anticipated to boost revenue growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to improving economic conditions and rising disposable income levels in emerging countries such as India and China. Furthermore, a rise in immigration from developed economies is also expected to contribute towards regional market development during the same period.
Growth Factors:
- Increasing incidence of congenital heart diseases due to changing lifestyle and environmental factors.
- Growing awareness about congenital heart diseases and their early diagnosis through various campaigns and initiatives by the government as well as private organizations.
- Technological advancements in the field of cardiac surgery which has led to better treatment outcomes for patients with congenital heart disease.
- Rising number of pediatric cardiac surgeries due to increasing prevalence of CHD in children population
Scope Of The Report
Report Attributes
Report Details
Report Title
Congenital Heart Disease Market Research Report
By Type
Medication, Surgical Therapy
By Application
Hospitals and clinics, Diagnostic centres
By Companies
Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic, BD, Boston Scientific, Merck, Eli Lilly, Mylan, Sun Pharmaceutical, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Congenital Heart Disease Market Report Segments:
The global Congenital Heart Disease market is segmented on the basis of:
Types
Medication, Surgical Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and clinics, Diagnostic centres
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Abbott Laboratories
- Roche
- GSK
- Sanofi
- Johnson & Johnson
- Medtronic
- BD
- Boston Scientific
- Merck
- Eli Lilly
- Mylan
- Sun Pharmaceutical
- AstraZeneca
Highlights of The Congenital Heart Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Surgical Therapy
- By Application:
- Hospitals and clinics
- Diagnostic centres
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Congenital Heart Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Congenital heart disease is a birth defect in which the heart does not develop normally. It can be caused by problems with the baby's genes, during pregnancy, or after birth. Congenital heart disease can cause serious health problems and may require surgery or other treatments to correct it.
Some of the major companies in the congenital heart disease market are Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic, BD, Boston Scientific, Merck, Eli Lilly, Mylan, Sun Pharmaceutical, AstraZeneca.
The congenital heart disease market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Congenital Heart Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Congenital Heart Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Congenital Heart Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Congenital Heart Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Congenital Heart Disease Market Size & Forecast, 2020-2028
4.5.1 Congenital Heart Disease Market Size and Y-o-Y Growth
4.5.2 Congenital Heart Disease Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Medication
5.2.2 Surgical Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and clinics
6.2.2 Diagnostic centres
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Congenital Heart Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Congenital Heart Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Medication
9.6.2 Surgical Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and clinics
9.10.2 Diagnostic centres
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Medication
10.6.2 Surgical Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and clinics
10.10.2 Diagnostic centres
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Medication
11.6.2 Surgical Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and clinics
11.10.2 Diagnostic centres
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Medication
12.6.2 Surgical Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and clinics
12.10.2 Diagnostic centres
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Medication
13.6.2 Surgical Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and clinics
13.10.2 Diagnostic centres
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Congenital Heart Disease Market: Competitive Dashboard
14.2 Global Congenital Heart Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Abbott Laboratories
14.3.4 Roche
14.3.5 GSK
14.3.6 Sanofi
14.3.7 Johnson & Johnson
14.3.8 Medtronic
14.3.9 BD
14.3.10 Boston Scientific
14.3.11 Merck
14.3.12 Eli Lilly
14.3.13 Mylan
14.3.14 Sun Pharmaceutical
14.3.15 AstraZeneca
